In a test, Vivior determined individual visual habits using the Vivior Visual Behavior Monitor and, based on this objective data, provided customized vision correction lenses to each of the test participants.
Vivior has cleared their system as a Class I medical device and is planning the market introduction later this year in Switzerland and the European Union.
Michael Mrochen, PhD, Chairman of the Board of Directors at Vivior, receives the Casebeer Award from the International Society of Refractive Surgery.
Vivior has signed an agreement with Kochoptik, a premium optical retailer in Switzerland. Kochoptik’s customers will wear Vivior’s Visual Behavior Monitor to provide a recommendation for an individualized vision care solution.
Vivior has recently closed an investment round with private investors from Europe and the US. With multiple million USD raised, it will finalize the currently running clinical study to assess the usability of their system and measure market acceptance. Based on these results, Vivior will register the system in Europe and the US to make it available to clinics, surgeons and patients.